Your browser doesn't support javascript.
loading
Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease.
Lutgens, Esther; Seijkens, Tom T P.
Affiliation
  • Lutgens E; Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Seijkens TTP; Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian's University, Munich, Germany.
J Immunother Cancer ; 8(1)2020 02.
Article in En | MEDLINE | ID: mdl-32034065
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Atherosclerosis / Immune Checkpoint Inhibitors Type of study: Etiology_studies / Risk_factors_studies Limits: Animals / Female / Humans / Male Language: En Journal: J Immunother Cancer Year: 2020 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Atherosclerosis / Immune Checkpoint Inhibitors Type of study: Etiology_studies / Risk_factors_studies Limits: Animals / Female / Humans / Male Language: En Journal: J Immunother Cancer Year: 2020 Document type: Article Affiliation country: